SAGE's Huntington's Disease Study Meets Primary Endpoint [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
potential treatment for patients with cognition dysfunction caused by Huntington's disease (HD), met its primary endpoint. Shares of the company were however down 2.8% on Jun 11 following the announcement of the news. The SURVEYOR study compared dalzanemdor versus placebo in participants with HD for a 28-day treatment period. The three main objectives of the SURVEYOR study were to evaluate the safety of dalzanemdor in participants with HD, to understand the extent of cognitive impairment in HD compared to healthy participants, as well as to better understand the relationship between changes in cognition and changes in function. The study met its primary endpoint by demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with HD prior to any treatment with dalzanemdor or placebo. The study demonstrated a small numerical difference in comparing dalzane
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Mirum (MIRM) Soars on Interim Data From Liver Disease Studies [Yahoo! Finance]Yahoo! Finance
- Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Acrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswire
- Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock [Yahoo! Finance]Yahoo! Finance
- Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
ACRV
Earnings
- 5/14/24 - Beat
ACRV
Sec Filings
- 5/21/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- ACRV's page on the SEC website